Recently, a small British study that was published in the Journal of Neurology, Neurosurgery & Psychiatry (1/30/13), suggested women who take valproate while pregnant have an increased risk of having children with autism and neurodevelopment problems. The study also suggested that damage to the fetus happens during the early stages of pregnancy.
Valproate-based anti-convulsants (drugs used to treat seizure disorders including epilepsy) include brand-name drugs Depakote, Depakene, Depacon and Stavzor–all of which are pregnancy risk Category D drugs. Category D drugs have shown positive evidence of fetal risk based on adverse reaction data from investigation or marketing experience or clinical studies in humans.
The Depakote infographic below highlights some of the potential adverse effects in newborns that have been associated with taking Depakote during the first trimester of pregnancy.